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populations in innate immune responses may represent a
mechanistic link to variation in susceptibility to infection or
response to vaccination.
Objective: Determine whether differences in innate immune
responses exist among infants from different continents of the
world.
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Open access under CC BY license.Results: We found that despite the many possible genetic and
environmental exposure differences in infants across 4
continents, innate cytokine responses were similar for infants
from North America, South America, and Europe. However,
cells from South African infants secreted significantly lower
levels of cytokines than did cells from infants from the 3 other
sites, and did so following stimulation of extracellular and
endosomal but not cytosolic PRRs.
Conclusions: Substantial differences in innate cytokine responses
to PRR stimulation exist among different populations of infants
that could not have been predicted. Delineating the underlying
mechanism(s) for these differences will not only aid in improving
vaccine-mediated protection but possibly also provide clues
for the susceptibility to infection in different regions of the world.
(J Allergy Clin Immunol 2014;133:818-26.)
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The first few years of life represent a period of marked
susceptibility to infectious diseases.1-3 Such vulnerability reflects
a state of age-dependent suboptimal immune-mediated protection
in early life.1,4,5Around theworld, theExpandedProgramon Immu-
nization and similar regional or national programs direct the immu-
nization of infants.6,7 These public health programs have greatly
contributed to diminishing infectious mortality and morbidity in
early life.8 Because the formulations and schedules of vaccination
do not vary considerably among countries, these vaccination strate-
gies rely on the notion that responses tovaccinationwouldbe similar
among infants living in different regions of theworld.7,9,10However,
it has become apparent that vaccine responses differ in infants from
varying geographic regions.11 The underlying mechanisms leading
todifferent vaccine responses indifferent populations remain largely
unknown.This lackof understandingprevents optimizationof infant
vaccine responses.Because innate immunitydirects adaptive immu-
nity, we reasoned that the first step in identifying the mechanistic
cause leading to variation in vaccine responses in infants from
diverse regions of the world would be to determine whether differ-
ences in innate immunity exist among different populations from
disparate regions. Several previous studies have described the
ontogeny of the innate pattern recognition receptor (PRR) response
in infants from different geographical regions.5 We set out to
contrast the PRR response to stimulation of infants across 4 conti-
nents (Africa,NorthAmerica, SouthAmerica, andEurope) by using
a highly standardized, stringently controlled innate immune pheno-
typing platform, ensuring the same experimental setup for all sites.
We found significant differences in innate immune responses toPRR
stimulation among infants from different populations.
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Ethics statement
This studywas conducted according to the principles expressed in theGood
Clinical Practice Guidelines, and the Declaration of Helsinki. This study was
approved by the University of British Columbia Ethics Board (protocol:
H11-01423). In addition, each site involved had obtained ethics approval in its
respective research center. Informed written consent from the next of kin,
caregivers, or guardians on the behalf of the minors involved in this study was
obtained for all study participants.Participant recruitment and enrollment
This study compared infants aged approximately 2 years from 4 different
sites: Vancouver, Canada; Brussels, Belgium; Quininde, Ecuador; and Cape
Town, South Africa. Canadian subjects were recruited from a pool of healthy
infants participating in other ongoing research studies at the University of
British Columbia.12 Subjects in Belgium were part of a pilot study for a larger
urban-based birth cohort study established at St Pierre Hospital (Brussels) in
collaboration with the Institute for Medical Immunology. Infants from
Ecuador were recruited within a rural-based population cohort study.13 South
African infants had been enrolled in an urban-based birth cohort established at
StellenboschUniversity.14 A subject was included in the study if the infantwas
considered healthy on the basis of a history-driven health assessment.
Subjects were excluded from the study if they had met 1 or more of the
following criteria: significant chronic medical condition, immune deficiency,
immunosuppression by disease or medication, cancer, bone marrow or organ
transplantation, receipt of blood products within 3 months, bleeding
disorder or major congenital malformation, or genetic disorder. Infants born
to HIV-positive mothers were also excluded.
Blood collection
Given that one of the major roles of the innate immune system is
sensing environmental changes,15,16 technical artifacts can easily plague
innate immune assessment.17 We thus implemented an experimental
approach with stringent focus on quality control and assurance. Every
step of the experiments was standardized and controlled across all sites.
All materials and reagents from blood draw to final analysis were tested
to ensure absence of innate immune activation substances as previous
work had shown lot-dependent variation.17,18 All blood draws were
performed in a hospital by a trained phlebotomist; the majority of the
samples were collected from the arm, with some from the neck. Peripheral
blood (3-5 mL) was drawn via sterile venipuncture into vacutainers
containing 143 units of sodium-heparin (Becton Dickinson [BD] Bio-
sciences, San Jose, Calif, catalog no. 8019839). Blood samples were
kept at room temperature and processed within hours of blood draw as
described previously.17,18Toll-like receptor stimulation and blood culture
Master mixes of all reagents were made in quantities adequate for the entire
study, frozen, and shipped under monitored conditions to all the 4 sites.The same person (K.S.) performed all aspects of the experiments at all sites by
using our well-established robust, validated, and quality-controlled innate
immune phenotyping protocol.12,17-20 In brief, deep 96-well (VWR, Missis-
sauga, Ontario, Canada) source plates with each well containing 1.3 mL of
a specific Toll-like receptor (TLR) ligand, were prepared by using sterile pro-
cedures under a laminar airflow hood. A total of 22 mL from each well of the
source plate was dispensed into each well of recipient 96-well round-bottom
polystyrene plates (Corning, Corning, NY) by using the Evolution P3
Precision Pipetting Platform (Perkin Elmer, Waltham,Mass). Recipient plates
were sealed with sterile aluminum plate sealers and frozen at2808C until use.
The 96-well plates contained the following TLR ligands with
specified concentrations and specifically targeted PRR: PAM3CSK4
(PAM; TLR2/1; InvivoGen, San Diego, Calif) at 1 mg/mL; polyinosinic-
polycytidylic acid (Poly I:C; TLR3; GE Healthcare, Fairfield, Conn) at 100mg/
mL; lipopolysaccharide (LPS; TLR4, InvivoGen) at 10 ng/mL; resiquimod
(R848; TLR7/8, InvivoGen) at 10mM;peptidoglycan (PGN; nucleotide-binding
oligomerization domain-containing protein 1/2 [NOD1/2], InvivoGen) at
10 mg/mL; muramyl dipeptide (MDP; NOD 2, InvivoGen) at 0.1 mg/mL; and
media alone. All TLR ligands were diluted in RPMI medium to obtain the
desired concentration.
Whole blood was diluted 1:1 with sterile prewarmed RPMI 1640, and 200
mL of the diluted blood was added to each well of the premade plates
containing the specific TLR ligands. Blood was incubated for 24 hours, after
which plates were centrifuged at 600g and subsequently 100 mL of the
supernatant was removed and frozen at 2808C for multiplex assay analysis
later. Samples were shipped on dry ice via World Courier, Inc, with a
temperature monitor in each shipment ensuring maintenance of the desired
temperature (2808C). Samples were stored at 2808C in the central analysis
site (Vancouver, Canada), and were all run within 12 months of collection.
Cytokine measurement
Supernatants were thawed at room temperature and assayed by multiplex
assay technique (Luminex: Upstate/Millipore ‘‘Flex Kit’’ system) by using the
high-biotin protocol with overnight incubation at 48C. The levels of the
following cytokines were measured: IFN-a2, IFN-g, CXCL10, IL-12p70,
IL-12p40, IL-6, TNF-a, IL-1b, CXCL8, CCL3, CCL4, and IL-10. Samples
were diluted 1-to-1 (or 20-, 80-, or 150-fold) with RPMI 1640 as needed to fall
within the standard curve. Beadlytes, biotin, and streptavidin-phycoerythrin
were used at half the manufacturer’s recommended concentrations. Assays
were read by using Luminex 200 Total System (Luminex, Austin, Tex)
running either the Bio-plex (Bio-Rad, Hercules, Calif) or the MasterPlex
(MiraiBio, San Francisco, Calif) software, and the downstream analysis was
performed by using Excel (Microsoft) and an in-house database.
Human IL-23 ELISA
To determine the IL-23 concentration, filtered supernatantswere diluted 1:4
in diluent contained in the human IL-23 (p19/p40) ELISA kit (eBioscience,
San Diego, Calif), and assays were performed according to the manufacturer’s
specifications. Plates were read at 450 nm with 570 nm subtraction on a
SPECTRAmax Plus. A 4-parameter sigmoid logistic curve was used to
generate the standard curve.
Statistical analysis
Kruskal-Wallis analysis was performed to compare the 4 sites for signi-
ficant variance among the median cytokine concentrations. Bonferroni test
was applied to correct for multiple comparisons. Dunn’s posttest was used to
determine which of the sites contributed to the significant differences.
Statistical analysis was conducted in Prism Version 6 (GraphPad Software).
Principal-component analysis
To visualize the data in an intuitive fashion, we plotted the data by using
principal-component analysis (PCA). The cytokine data were log-transformed
and then subjected to PCA by using GINKGO: Multivariate Analysis
System.21,22 The data were plotted by using Tableau visualization software
TABLE I. Demographics of the infants at each of the 4 sites
Belgium Canada Ecuador South Africa
N 14 20 43 20
Infant characteristics
Mean age (mo), mean 6 SD 24.7 6 4.3 19.1 6 0.8 26.7 6 1.28 24.7 6 0.6
Birth weight (g), mean 6 SD 2996.2 6 796.3 3339.6 6 448.2 3475.1 6 988.3 3018.4 6 383.6
Birth mode (vaginal/c-section) 13/1 11/13 34/9 20/0
Gestational age, mean 6 SD 38.4 6 3.4 39.2 6 1.5 38.9 6 1.1 37.8 6 2.4
Premature < 37 wk (% of total) 2 (14%) 1 (4.5%) 0 (0%) 3 (15%)
Weight (g), mean 6 SD 13364.3 6 1786.1 11190.9 6 1392.5 11501.16 6 1010.7 11205.0 6 1300.7
Height (cm), mean 6 SD 92.2 6 4.6 82.2 6 3.0 84.3 6 2.5 84.4 6 0.91
WAZ, mean 6 SD 0.69 6 1.2 20.05 6 0.9 20.32 6 0.93 20.58 6 0.95
LAZ, mean 6 SD 1.56 6 0.8 20.30 6 0.9 20.78 6 1.49 21.07 6 1.20
WLZ, mean 6 SD 20.18 6 1.4 0.17 6 1.0 0.16 6 0.79 20.03 6 0.87
LAZ, Length-for-age Z score; WAZ, weight-for-age Z score; WLZ, weight-for-length Z score.
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could not be assessed for each of the enrolled subjects; the IL-23 data were
thus not included in the principal-component cluster analysis but were
included in the box-plots and statistics.Z-score analysis
The World Health Organization anthropometric calculator was used to
determine each participant’s individual z score (WHOAnthro version 3.2.2).23RESULTS
Cohort characteristics
We selected 4 populations that differ in many of the elements
presumed to be relevant for variation in risk for infection or
vaccine responses. Most importantly genetic variation among the
hosts and differences in environmental exposure such as
residence in resource-poor versus resource-rich settings. We
chose to study innate immunity in infants aged 2 years to ensure
that all had completed locally recommended infant vaccinations
(see Fig E3 in the Online Repository at www.jacionline.org). The
characteristics of the study population at the time of sample
collection are described in Table I. Based on the WHO
Child Growth Standards, the mean weight-for-age Z score,
length-for-age Z score, and weight-for-length Z score of each
subject in all cohorts were within less than 2 SDs of the mean
(Table I). This indicated that the infants in our cohorts were
within the average range for normal child growth standards.24,25
Furthermore, all infants were healthy based on clinical history
taken at the time of sample collection.Innate cytokine responses
We chose 13 cytokine target read-outs to broadly cover the
most important functional categories: innate cytokines supporting
TH1-type adaptive immunity (IFN-a, IFN-g, CXCL10, and
IL-12p70), innate cytokines supporting TH17-type adaptive im-
munity (IL-12p40, IL-6, and IL-23), proinflammatory cytokines
(TNF-a and IL-1b), chemokines (CXCL8, CCL3, and CCL4),
and the regulatory cytokine IL-10. There were no significant
differences in response between males and females (data not
shown); thus the sexes were pooled for analysis for each site.
PCA (Fig 1) allowed us to compress the many dimensions
(12 eigenvectors, each representing 1 cytokine) following
response to all 7 PRR agonists for visual analysis.22,26 In Fig 1,
each color represents a ligand and each dot represents 1 infantfor a particular stimulatory condition. The percentage of PCA1
(55.45%) and PCA2 (19.45%) contributing to overall variance
between subjects and stimuli is depicted on the x-axis and the
y-axis, respectively. The primary component separating data
points in Fig 1 (ie, principle component 1 [PC1]) appears to be
the overall strength of the stimulation, as the weakest stimulant
(unstimulated samples) clusters furthest to the right while the
overall strongest stimulant (R848) clusters furthest to the left.
PC2, however, separates the clusters on the basis of the PRR
location; that is, endosomal PRR (TLR3 and TLR7/8) responses
cluster higher on the axis, while cell surface and cytoplasmic PRR
(TLR2/1, TLR4, and NOD) responses cluster lower down. The
eigenvectors of the PCA are shown in Fig 1, B. This allows further
delineation of contributors for the clustering along PC2, in that
the endosomal TLR-driven clusters (ie, those located higher up
in the plot) are largely composed of TH-1 supporting innate
cytokines (IFN-a, IL-12p70, and IFN-g) while the cell-surface
TLR- and NOD-driven clusters (ie, those clustering in the lower
left quadrant) are composed of the proinflammatory cytokines
(TNF-a, IL-1b, etc). This pattern is also consistent with the
known function of PRRs, in that endosomal PRRs mainly
recognize intracellular pathogens and their activation leads to
the production of innate cytokines supporting cell-mediated
TH1-type immunity (ie, IFN-a and IL-12p70).
5,27 Visual analysis
indicated that the largest variance between samples was
determined by the type of PRR stimulation (Fig 1). Furthermore,
the fact that the PRR-induced responses led to similar clustering
for most infants from all 4 sites suggests that basic biological
mechanisms functioning in all populations represented the
strongest component contributing to clustering.Endosomal TLR responses: South African infants
underresponded
TLR7/8 (R848). In Fig 2, A, we highlighted responses of
all 4 cohorts to R848 (a TLR7/8 ligand) stimulation. The
Belgian, Canadian, and Ecuadorian responses tightly clustered
together at the upper left-hand quadrant of the ordination, clearly
apart from the unstimulated samples. The response of infants in
the South African cohort localized as a distinct and separate
cluster between the Belgian-Canadian-Ecuadorian stimulated
cluster and the cluster of all the unstimulated samples. Compared
with the other geographic cohorts, this pattern suggests that
South African infants respond differently to stimulation with
R848.
FIG 1. PCA ordination of the innate immune response for all subjects measured by cytokine secretion in
response to PRR agonists. A, The variance in cytokine response (12 dimensions) to all ligands. Each color
represents a ligand, while each dot represents 1 subject. B, Eigenvectors show the particular correlations
of individual cytokines to the ordination of the PCA in A.
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between populations (see Fig E1 in the Online Repository at
www.jacionline.org). Kruskal-Wallis analysis (Table II) revealed
that with the exception of CXCL8, all cytokines produced in
response to TLR7/8 stimulation were detected at significantly
different levels among sites. Dunn’s posttest (Table II) further
revealed that South African infants’ responses were solelyresponsible for the significant variation among sites, with South
African infants responding consistently lower than infants from
the other sites. For TH1-supporting innate cytokines, production
in South African versus Ecuadorian and Canadian infants
differed for all, and South Africa versus Belgium for most
cytokines. For TH17-supporting innate cytokines, differences in
production between South African versus Ecuadorian infants
A B
C
−
−
−
−− − − − −
−
−
−
− − − − − −
−
−
−
− − − − − −
FIG 2. Innate immune response to PRR stimulation. PCA ordination of the R848 response is depicted in
panel A, LPS in panel B, and PGN in panel C. Each dot represents 1 subject, symbol represents a site, and
color represents the stimulation (open [Belgium, Canada, and Ecuador], red [South Africa] for given
stimulation).
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significant difference betweenSouthAfrican andCanadian infants’
responses, and IL-6 between South African and Belgian subjects.
For the proinflammatory cytokines, significant difference between
sites originated between South Africa and all other sites. Produc-
tion of the proinflammatory chemokines was also significantly
different between all sites, with South African infants producing
less than Belgian, Canadian, or Ecuadorian infants. Furthermore,
the antiinflammatory cytokine IL-10’s median concentration
detected following TLR7/8 stimulation was lowest in South
African infants, with Belgian infants producing the most.TLR3 (Poly I:C). PCA analysis of Poly I:C (a TLR 3 ligand)
stimulation also led to similar responses at all sites except South
Africa (see Fig E2,A, in the Online Repository at www.jacionline.
org). South African infants produced low TH1-supporting and
proinflammatory cytokines. However, the magnitude of the
difference in cytokine production between the response of South
African subjects and those from the other sites was not as
large following TLR3 stimulation as it was following TLR7/8
stimulation. For example, the median response of the Belgian
cohort located marginally above the South African cohort.
Furthermore, Ecuadorian subjects stimulated with Poly I:C
TABLE II. Statistical analysis of each cytokine per stimulation at all sites
IFN-a2 IFN-g CXCL10 IL-12p70 IL-12p40 IL-6 IL-23 TNF-a IL-1b CXCL8 CCL3 CCL4 IL-10
Unstimulated
Global .003 .0956 <.0001 .6486 .2065 .0024 <.0001 .0002 .3932 .0153 <.0001 .3424 .838
SAF vs BLG NS * * NS
SAF vs CND    
SAF vs ECD NS NS NS NS
BLG vs CND * NS NS 
BLG vs ECD NS NS NS NS
CND vs ECD  * * 
R848
Global <.0001 <.0001 <.0001 <.0001 <.0001 <.0001 .0036 <.0001 <.0001 .0053 <.0001 <.0001 <.0001
SAF vs BLG  *  NS NS   *   
SAF vs CND      *     
SAF vs ECD           
BLG vs CND NS NS NS * NS NS NS NS NS NS 
BLG vs ECD NS NS NS  * NS NS * NS NS 
CND vs ECD NS NS NS NS NS  NS NS  NS NS
pIC
Global <.0001 <.0001 <.0001 <.0001 <.0001 .1267 <.0001 <.0001 <.0001 .0041 <.0001 <.0001 .0031
SAF vs BLG NS NS  NS  NS NS NS NS NS
SAF vs CND   *  NS   *  
SAF vs ECD      NS    
BLG vs CND   NS NS  NS NS   NS
BLG vs ECD   NS  NS NS    
CND vs ECD NS NS NS NS   NS NS NS *
LPS
Global .0063 <.0001 <.0001 .1411 <.0001 <.0001 .0036 <.0001 <.0001 .0002 <.0001 <.0001 <.0001
SAF vs BLG NS    * NS    
SAF vs CND  *     NS   
SAF vs ECD          
BLG vs CND  NS NS NS NS  NS NS NS 
BLG vs ECD NS NS NS NS NS NS NS NS NS 
CND vs ECD * *  NS NS  NS NS NS NS
PAM
Global .0145 .6916 <.0001 .6243 <.0001 <.0001 .0001 <.0001 <.0001 <.0001 <.0001 <.0001 <.0001
SAF vs BLG    NS      
SAF vs CND NS NS NS NS NS NS NS NS NS NS
SAF vs ECD    NS      
BLG vs CND * NS *  NS NS  NS NS 
BLG vs ECD NS NS NS NS NS NS NS NS NS NS
CND vs ECD * NS  NS      
PGN
Global .0174 .042 <.0001 .593 <.0001 <.0001 <.0001 <.0001 <.0001 <.0001 <.0001 .0044 <.0001
SAF vs BLG NS NS  NS NS NS   
SAF vs CND NS  NS NS   NS NS 
SAF vs ECD * NS   NS NS   
BLG vs CND *   * NS   NS NS
BLG vs ECD NS NS NS NS NS NS NS NS 
CND vs ECD        NS NS
MDP
Global .005 .2408 <.0001 .7072 .9201 .0254 <.0001 <.0001 .0006 <.0001 .0007 <.0001 .0477
SAF vs BLG  NS * * NS
SAF vs CND NS  * NS NS
SAF vs ECD  NS   
BLG vs CND  NS NS  NS
BLG vs ECD NS NS NS NS 
CND vs ECD  *   
Note. The Kruskal-Wallis test for all 4 sites (global) was corrected for multiple comparisons by using the Bonferroni test (significant P value is P < .000595).
BLG, Belgium; CND, Canada; ECD, Ecuador; NS, not significant; SAF, South Africa.
*Dunn’s post hoc test was applied to each site paring (statistical significance P value was <.05).
Dunn’s post hoc test was applied to each site paring (statistical significance P value was <.01).
Dunn’s post hoc test was applied to each site paring (statistical significance P value was <.001).
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another below the main cluster composed of Belgian and
Canadian subjects. The separation of the Ecuadorian subjects
into 2 clusters is also reflected in the larger CI of median cytokine
concentrations depicted in Fig E1.
Statistical analysis (Table II) revealed that cytokines were
produced at significantly different levels among the 4 sites
following TLR3 stimulation, with the exception of IL-6,
CXCL8, and IL-10. Dunn’s posttest of TH1-supporting and
proinflammatory cytokine production revealed that the variation
mainly originated from South African infants. Production of
IL-10 following Poly I:C stimulation was not above background
for subjects from any of the 4 sites.Responses to cell surface TLRs: South African
infants underresponded
TLR4 (LPS). LPS stimulation of TLR4 resulted in clustering
of response for infants from all sites except from South Africa
(Fig 2, B). This illustrates that compared with subjects from other
sites, whole blood from South African infants also underres-
ponded to TLR 4 stimulation. Most cytokines were detectable
except IFN-a and IL-12p70, which were not produced above
background by infants from any of our cohorts. The median
cytokine concentration in response to TLR 4 stimulation for
each individual cytokine response was consistently lowest for
South African infants (Fig E1). Specifically, TH1 cytokine pro-
duction in response to LPS revealed a low response pattern in
South African infants, while the infants from the other 3 sites
showed a higher median response. While the response overall
appeared to have high variation between subjects even within a
given site (note the larger spread of the CI), statistical differences
were still detected (Table II). Dunn’s posttest identified that the
greatest statistical difference for IFN-g was found between
Canadian and South African or Belgian children. Production of
TH17-supporting cytokines following LPS stimulation also
identified South African infants as having the lowest response
to LPS. Similarly, production of proinflammatory cytokines and
chemokines showed the weakest response in South African and
the highest response in Canadian subjects; Dunn’s comparison
identified the greatest statistical differences between South Afri-
can versus Canadian and Ecuadorian infants. Production of IL-10
in response to LPS was again lowest in South African subjects.
TLR2/1 (PAM). Overall, PAM stimulation resulted in the
least obvious PCA cluster separation between sites for surface
TLRs. However, only the response of the South African cohort
strongly overlapped with the unstimulated samples, indicating an
overall lower response, while the response of the subjects from
other sites, primarily from Ecuador and Belgium, clearly
clustered away from the unstimulated samples (Fig E2, B).
With the exception of CXCL10, TH1-supporting cytokines were
not produced above the background for subjects from any site
in response to PAM (Fig E1). Dunn’s posttest of CXCL10 produc-
tion following TLR2/1 stimulation revealed that infants from
South Africa and Canada did not vary from each other in their
response, but infants from both sites differed significantly in
their response from that of infants from Belgium and Ecuador
(Table II). The same relationship was found for the production
of TH17-supporting cytokines, with infants from Belgium and
Ecuador producing a higher median concentration than did in-
fants fromSouth Africa and Canada; however, only SouthAfricaninfants varied statistically from Belgian and Ecuadorian children.
The production of proinflammatory cytokines was lower for
infants from South Africa and Canada versus those from Belgium
or Ecuador. The response of South African infants varied
significantly from Ecuadorian and Belgian infants for all
proinflammatory cytokines. The same statistical relationship
was also detected for the production of IL-10.Cytosolic PRR responses: Similar responses in all
cohorts
NOD2 and TLR2/1 (PGN). Following PGN stimulation, the
response of infants from all the sites, including South Africa,
clustered tightly together (Fig 2, C). On closer inspection, we
found that none of the TH1 cytokines were produced above
background. Canadian and South African infants all produced
significant levels of TH17-supporting innate cytokines following
PGN stimulation, while Belgian and Ecuadorian infants re-
sponded weakly. Production of the proinflammatory cytokines
and chemokines was also readily detected in infants from all sites,
with differences between the 4 sites. Dunn’s comparison of IL-10
revealed strong significant variation between infants from South
Africa (low) and those from Canada, Belgium, or Ecuador
(Table II).
NOD2 (MDP). Following stimulation withMDP, the response
clusters visually overlapped with the unstimulated clusters for all
sites, suggesting an overall very low response (Fig E2, C). TH1-
and TH17-supporting, as well as anti-inflammatory, cytokines
were not produced above background; the production of only
CXCL10, TNF-a, CXCL8, and CCL4 were detectable. As with
the other NOD ligand (PGN), the response of South African
infants was more similar to that of infants from the other sites
as compared with the TLR stimuli. Specifically, the production
of CXCL10, TNF-a, CXCL8, and CCL4 in South African infants
was similar to that in Canadian infants, while responses in both
these groups were significantly lower than the responses of
Belgian and Ecuadorian infants.DISCUSSION
Our study represents the first test of the hypothesis that innate
cytokine production in infancy following PRR stimulation varies
across continents. By using a stringently controlled, robust, high-
throughput innate immune phenotyping platform, we identified
similarities as well as differences in innate immune response to
PRR stimulation of samples collected from infants across 4
continents. When contrasting the infant innate cytokine response
based on country, it emerged that the responses of South African
infants formost stimuli were distinct from the responses of infants
at the 3 other sites. This was notable both in the degree of
separation of the clusters and in the consistency displayed across
multiple stimuli. However, while the innate cytokine response to
PRR stimulation in South African infants was found to be lower
for nearly all parameters tested, it was similar to infants from the
other sites for the NOD2 ligands PGN and MDP. This suggests
that it was not an overall inability of South African infants to
respond with cytokine production to PRR stimulation but that
variation in the pattern of innate cytokine production following
PRR stimulation in infancy varied by geographic region in
response to the particular type of PRR stimulation. More
specifically, the response to endosomal as well as cell surface
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was more similar among infants from different continents. This
suggests differences in particular downstream signaling cascades
in infants from South Africa versus the other sites.
Differences in innate immune status have been ascribed to
variation in environmental exposures ranging from birth mode,
feeding mode, infections, vaccination, and resource-rich versus
resource-poor region of residence (reviewed in Kollmann et al5
and Kollmann28). However, based on these previous studies, the
results of our current study—indicating striking differences be-
tween the innate immune response of SouthAfrican infants versus
those fromEcuador, Belgium, andCanada—were not predictable.
Our work with Canadian infants revealed an overall steady
increase from birth onward in the production of TH1-supporting
innate cytokines following TLR stimulation, while TLR-
induced anti-inflammatory and TH17-supporting innate cytokines
progressively declined over the first 2 years of life.5,12,19 This was
consistent with findings from other resource-rich regions of the
world, for example, Belgium and theNetherlands.29,30 In contrast,
with a similar experimental approach we revealed a decline of
most TLR-induced innate cytokine responses in South African in-
fants over the first year of life froma high at 2weeks of age.20 Such
decline over the first year of life was consistent with previous
studies from The Gambia20 as well as Ecuador.31 Furthermore,
cord bloodmononuclear cells fromPapuaNewGuinean newborns
produce lower IL-6 and type-I IFN responses toTLR2 stimulation,
and lower TNF-a responses to TLR4 stimulation as compared
with Australian newborns.32 Over the first 2 years of their lives,
Papua New Guinean infants then develop increasing IL-6 and
IFN-g responses to TLR2 and TLR3 agonists in parallel with sus-
tained high IL-10 responses.33 Based on these data, it was hypoth-
esized that infants born in resource-rich countries (ie, Australia)
exhibit increased innate immune reactivity at birth than do infants
born in resource-poor countries (ie, Papua New Guinea).33,34
The data presented here strongly argue that differences be-
tween regionally disparate groups in innate cytokine production
following PRR stimulation were unlikely due to resource-rich
versus resource-poor influence33,34 nor impacted by latitude,35 as
infants from Ecuador (considered resource-poor) produced as
much or more of any innate cytokine as did infants from Belgium
or Canada (both considered resource-rich), and certainly more
than did infants from South Africa (considered resource-poor).
Furthermore, given that the subjects in our study from South
Africa and Ecuador received Bacillus Calmette-Guerin around
birth while subjects from Belgium and Canada did not, newborn
Bacillus Calmette-Guerin immunization also appears unlikely to
be themain driver for observed differences at age 2 years. Of note,
Djuardi et al36 also found no clear effect of Bacillus Calmette-
Guerin vaccination on the innate immune ontogeny. While the
overall vaccination schedule was similar for all infants across
the 4 sites, differences in vaccine composition (eg, acellular vs
whole-cell pertussis) or exact age of receipt of vaccines differed;
we thus cannot exclude that such variation in standard childhood
vaccination might be responsible for our observed differences.
We also interpret our data to indicate that differences in feeding
mode (length of breast-feeding; breast- vs bottle-feeding etc)
were unlikely major contributors to the differences we observed,
as feeding mode differed vastly between and within sites.
However, we can not exclude that feeding mode would not lead
differences in innate immune development when comparing
different feeding modes within a given population.37 Parasiticinfections, which are common in South Africa and Ecuador early
in life, but rare in Belgium and Canada, alsowere unlikely to offer
a general explanation for the variation between populations we
observed. However, we did not measure this directly in either
the mothers or in our study subjects; thus, we cannot firmly
exclude this possibility.37 Our data comparing secreted cytokine
levels in the supernatant of whole blood cultures does not permit
identification of the source or origin of observed differences in
innate cytokine production; differences could thus be due to
cell-intrinsic (eg, signaling mechanisms) or cell-extrinsic (eg,
cell composition) factors, or a combination of both.
Differences in host genetic composition are known to influence
innate immunity.38 We have recently shown that variation in
innate immune responses can be influenced by single nucleotide
polymorphisms within the PRR pathways and that the prevalence
of these single nucleotide polymorphisms varies within different
racial backgrounds.39 It is thus entirely possible that genetic
differences (including variation in HLA) between our populations
contributed to the differences in functional responses we
measured between sites. The relatively small SD for the cytokine
responses of each cohort suggests that genetic heterogeneity
within each site was smaller than between sites. We also noted
that the composition of enrolled subjects within each of our
cohorts included a wide range of ancestral origin. We thus do
not believe that differences in genetic background alone can
explain the striking difference between responses to PRR
stimulation of infants born and raised in South Africa versus
our other 3 sites. We hypothesize that the particular constellation
of microbiota in South African infants may contribute to our
observed difference in innate immune phenotype. This hypothesis
is based on the timing of the decline in innate responsiveness in
South African infants (between 6 and 12 months of age) and
the persistence of the lower innate responsiveness into
adulthood.20 A stable human intestinal microbiota is established
over the first year of life and then persists into adulthood.40,41
Infant mortality varies greatly between different regions of the
world.3 In our 4 cohorts between 2005 and 2010, for every 1000
live births Belgium registered 5 deaths per annum before the age
of 5 years, Canada 6, Ecuador 26, but South Africa 79.42 Low
birth weight and gestational age often correlate with increased
mortality43; the subjects in our cohort were of normal average
birth weight, and the number of infants with lower gestational
age at delivery in each cohort was similar between sites
(Table I). These variables are therefore less likely to have caused
the low innate immune response in only South African infants.
Patterns of innate immune ontogeny in North American or
European infants have been shown to correlate with particular
age-dependent windows of vulnerability to specific infections.5
It is thus entirely possible that the overall lower response of South
African infants at age 2 years to PRR stimulation reflects
enhanced susceptibility to infection, and thus may be of clinical
relevance.
The major limitation of our study is the small sample size; we
thus cannot fully exclude the potential for a type 1 statistical error
even after correcting for multiple comparisons. Our findings will
need to be replicated in larger studies at the same and additional
sites. Our recruitment strategy also was not representative of each
population in its entirety. Notwithstanding these limitations, our
data allow formulation of a molecular mechanistic hypothesis
(‘‘population-based differences exist in signaling downstream of
surface and endosomal PRRs, but not of cytoplasmic PRRs’’),
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(‘‘differences in vaccine responses and infant mortality may
relate to differences in innate PRR response’’). Each of these
hypotheses can now be tested in focused studies.
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Clinical implications: Differences in innate immunity of 2-year-
old infants across 4 continents correlate with variation in
susceptibility to infectious morbidity and mortality.REFERENCES
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FIG E1. Cytokine production comparison for all 4 sites per cytokine and stimulation. Box-whisker plots,
with the median highlighted for each site (the error bars 5 90% CI). A, The production of TH1- and
TH17-supporting innate cytokines. B, The production of the proinflammatory cytokines and chemokines,
as well as the regulatory cytokine IL-10.
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FIG E2. Innate immune response to PRR stimulation. PCA ordination of the Poly I:C response is depicted in
panel A, PAM in panel B, and MDP in panel C. Each dot represents 1 subject, symbol represents a site, and
color represents the stimulation (open [Belgium, Canada, and Ecuador], red [South Africa] for given
stimulation).
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FIG E3. A simplified vaccine schedule for infants at each site.
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